Catheter Precision raises $3.47M in fresh convertible preferred round

What's the deal? Catheter PrecisionDealroom has a profile for this one. Try Dealroom → (NYSE American: VTAK) has closed a $3,470,000 raise through the sale of 3,470 shares of newly designated Series C-3 Convertible Preferred Stock. The company disclosed the deal in a Form 8-K filing dated July 15, 2026. Each share carries a stated value of $1,000.

How it works: The preferred stock converts into common shares at an initial price of $0.632, with a floor of $0.35 that the company may waive. It ranks senior to common stock for dividends and liquidation, meaning Series C-3 holders get paid first.

Why now? This is a quick re-raise, signalling the company returned to the market soon after a prior financing. Stockholders approved the issuance at a special meeting on April 15, 2026, and the resale registration statement took effect on July 10.

What's the endgame? Management says the capital gives it "additional financial flexibility" to pursue strategic and operational goals. The offering was sold only to accredited investors under exemptions from SEC registration, with no general solicitation.

What could go wrong? Conversion of the preferred stock would dilute existing common shareholders, particularly if the floor price is waived or the conversion price adjusts downward. The certificate of designation also restricts the company from paying cash dividends on common stock and redeeming junior securities.

The signal: For a small-cap medical device maker, repeated recourse to convertible preferred financing points to ongoing capital needs and a shareholder base facing steady dilution pressure. The senior ranking and conversion terms tilt the deal toward new investors, a common trade-off for companies raising at modest scale.

Read more: minichart.com.sg

Image credit: Generated with Gemini